The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The role of autoSCT in Waldenström’s macroglobulinemia and eligibility criteria
Charalampia Kyriakou, MD, PhD, University College London Hospital (UCLH), London, UK, discusses the role of autologous stem cell transplantation (autoSCT) in treating Waldenström’s macroglobulinemia (WM). Despite advances in other therapies providing deep and durable responses, autoSCT remains a viable option for patients who have failed multiple lines of treatment and are fit for the procedure. This interview took place at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
